Sign up
Pharma Capital
EPIC: IXI
Market: AIM
52-week High/Low: 43.00p / 18.78p
Sector: Pharma & Biotech
Market Cap: 14.97M
Website: www.ixico.com

IXICO’s TrialTracker® platform and Artificial Intelligence (AI) software algorithms are used by the global pharmaceutical industry to collate and interpret brain scan data from MRI and positron emission tomography (PET) scanners, as well as to make sense of real-world data collected using wearable biosensors.  Our specialist data analytics services identify and measure unique biomarkers...

IXICO PLC

www.ixico.com

Interactive graph

col 3
col 4
col 5
col 6

Big picture - Why invest in IXICO PLC

IXICO PLC Snapshot

As a trusted partner to the global biopharma industry, our technology enabled specialty services are used to, select patients for clinical trials, assess the safety and efficacy of new drugs in development and in post marketing surveillance.

Our strong scientific heritage and deep understanding of neurological diseases enable us to collaborate with clinical, academic and pharmaceutical partners to develop and deploy new digital technologies targeted at improving the assessment of patient outcomes.

 

About IXICO

 

Our Values


Expertise
We are neuroscience experts in image data management and analysis.

Innovation
Our greatest assets are our talented people developing and deploying innovative digital technologies.

Quality
Quality drives our operational excellence. We support our people to be the best they can be through continuous learning and development.

Integrity
We conduct our business to the highest ethical standards and strive to be a trusted partner of choice.

 

Technology

Our technologies are powering some of the most important clinical trials in neuroscience today.

Image biomarkers

Digital biomarkers

Data Platforms

Innovation and AI

 

Therapeutic Areas

IXICO's team of scientists, researchers, global operations and regulatory specialists works across a spectrum of neurological conditions to provide insight and support delivery of your clinical programme.

 
 
 
 

We are recognised internationally as experts in neuroscience data management and analysis. Since 2004, our technology and scientific expertise have been selected to support clinical trials for the majority of the top pharmaceutical and speciality biotechnology companies.

Read more about some of the neurological conditions we cover below, and see how we help monitor for progressive multifocal leukoencephalopathy (PML) here.

 

Alzheimer's Disease

 

READ MORE

Parkinson's Disease

 

READ MORE

Huntington's Disease

 

READ MORE
 

Multiple Sclerosis

 

READ MORE

Progressive Supranuclear Palsy

 

READ MORE

Other Rare Neurological Diseases

 

READ MORE

 

Charles Spicer

NON-EXECUTIVE CHAIRMAN

Charles joined the Board of IXICO in 2013. He is an experienced Director of, and adviser to, public and private companies primarily in the medtech and life science sectors. He is Non-Executive Chairman of Realm Therapeutics plc, Creo Medical Group plc and 11 Health Technologies Limited and chairs the UK Department of Health Invention for Innovation Funding Panel.

Giulio Cerroni

CHIEF EXECUTIVE OFFICER

Giulio joined IXICO as Chief Executive Officer in February 2017. He has over 30 years of experience in the life sciences sector and a track record of growing business operations in Europe, the US and Asia. Prior to IXICO, Giulio held global leadership roles at ThermoFisher Scientific and the LGC Ltd, where he transformed the scale of LGC’s Genomics division, completing 3 acquisitions in under 18 months. Giulio was a member of the executive leadership responsible for the successful sale of the LGC Ltd to global investment firm, KKR & Co. Inc.

Tim Sharpington

NON-EXECUTIVE DIRECTOR AND SENIOR INDEPENDENT DIRECTOR

Tim has more than 25 years’ experience in the life sciences sector with various pharmaceutical, biotechnology and pharmaceutical service companies in Europe and the US. He has broad experience in drug development, product licensing, mergers, acquisitions and fundraisings. Tim is currently Chief Operating Officer at hVIVO plc. His previous positions include Chief Executive Officer at Phytopharm plc and Serentis Limited and Executive Vice President at Vectura plc. Tim joined the Board of IXICO in 2013 and chairs the Remuneration Committee.

Mark Warne

NON-EXECUTIVE DIRECTOR

Mark joined the Board of IXICO in 2016. He is Chief Executive Officer of DeepMatter Group plc. Mark is widely recognised in the UK and international life sciences sector, having spent almost 10 years at IP Group plc, a leading intellectual property commercialisation company, where he led the Healthcare team. Mark is a Non-Executive Director of hVIVO plc.

John Bradshaw

NON-EXECUTIVE DIRECTOR

John is a chartered accountant with more than 20 years’ experience as a Chief Financial Officer with venture capital-backed and listed companies. He is the Chief Financial Officer of Syncona Investment Management Limited, the Investment Manager of Syncona Limited. He is a Non-Executive Director and Audit Committee Chair of Creo Medical plc.  John joined the board of IXICO in 2013 as a Non-Executive Director and is Chair of the Audit Committe and a member of the Remuneration Committee.

 

Shareholder information

 
 
 

Directors and their interests

Director's name Number of shares held Percentage %
Charles Spicer 333,196 0.71
Giulio Cerroni 84,800 0.18
John Bradshaw 35,500 0.08
Tim Sharpington 15,100 0.03
Mark Warne 5,400 0.01

 

IXICO plc

4th Floor
Griffin Court
15 Long Lane
London
EC1A 9PN

Company Information
IXICO plc is incorporated and registered in England and Wales with registered number 03131723.

The Group operates from its headquarters in London, UK.

Registered Office
4th Floor, Griffin Court, 15 Long Lane, London EC1A 9PN

Advisers
Nominated adviser and broker

Shore Capital Stockbrokers Limited
Bond Street House, 14 Clifford Street, London W1S 4JU
T +44 (0)20 7408 4080
W www.shorecap.co.uk

Registrar
Equiniti Registrars Limited
Aspect House, Spencer Road, Lancing, West Sussex, BN99 6DA
T +44 (0)871 384 2030
W www.equiniti.com

Chartered accountants and statutory auditors
Grant Thornton UK LLP
101 Cambridge Science Park, Milton Road, Cambridge CB4 0FY
T +44 (0)1223 225600
W www.grantthornton.co.uk

Legal advisers
Bristows LLP
100 Victoria Embankment, London, EC4Y 0PH
T +44 (0)20 7400 8000
W www.bristows.com

Financial public relations
FTI Consulting LLP
200 Aldersgate, Aldersgate Street, London, EC1A 4HD
T +44 (0)20 3727 1000
W www.fticonsulting.com

View full IXI profile View Profile
View All

Market Reports Including IXI

VIEW ALL

Executive video interviews

VIEW ALL VIDEOS

© biotech Capital 2019

Biotech Capital, a subsidiary of Proactive Investors, acts as the vanguard for listed biotech companies to interact with institutional and highly capitalised investors.
Headquartered in London, Biotech Capital is led by a team of Europe's leading analysts and journalists, publishing daily content, covering all key movements in the Biotechnology market.